Nantes, France

Pierre Layrolle

This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignees: Chu Nantes, The University of Nantes. Active years: 2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre Layrolle. Retrieved from https://idiyas.com/inventor/pierre-layrolle

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Pierre Layrolle: Innovator in Bone Regeneration

Introduction

Pierre Layrolle is a notable inventor based in Nantes, France. He has made significant contributions to the field of bone regeneration, particularly through his innovative patent.

Latest Patents

Layrolle holds a patent for a bone regeneration membrane and a method for forming this membrane. This invention is crucial for enhancing the healing process in bone-related injuries and conditions.

Career Highlights

Throughout his career, Pierre Layrolle has worked with esteemed institutions such as Université de Nantes and Chu Nantes. His work in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

He has collaborated with notable colleagues, including Alain Hoornaert and Jerome Sohier, which has further enriched his research endeavors.

Conclusion

Pierre Layrolle's contributions to bone regeneration through his patent and collaborations highlight his importance in the field of medical innovation. His work continues to impact the way bone injuries are treated and managed.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…